Business
Further CEO Share Purchase
Renalytix plc announced that its Chief Executive Officer, James McCullough, purchased an additional 750 American Depositary Shares (ADS) on February 12, 2026, at an average price of $3.15 per ADS, for a total transaction value of $2,362.50. Following this purchase, Mr. McCullough now holds an interest in 3,430,096 ordinary shares, representing 0.78% of the company's issued share capital. This transaction indicates continued confidence from the CEO in the company's prospects. Disclaimer*
About this update from Renalytix Plc
[{"type":"text","content":"\n\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nFurther CEO Share Purchase\n \nLONDON and NEW YORK, 13 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, announces that on 12 February 2026 James McCullough, Chief Executive Officer, bought a further 750 American Depositary Shares (ADS) at an average price of US$3.15 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.\n \nFollowing these purchases, James McCullough is interested in 3,430,096 Ordinary Shares1 representing 0.78% of the issued share capital of the Company.\n \n1James McCullough shareholding includes ordinary shares held through his family trust, The McCullough 2020 Irrevocable Trust.\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nJeff Keating / David Hignell (Corporate Finance)\nVadim Alexandre (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOberon Capital (Joint Broker)\n\n\nTel: +44 (0)20 3179 5300\n\n\n\n\nMike Seabrook / Nick Lovering\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n\n \nAbout Renalytix (www.renalytix.com)\n \nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.\n \nUnrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidne...